TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27450474
Drug: Intravenous 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9 mg/kg alteplase plus standard care
Study: 18971727
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous platelet-rich fibrin
Study: 12651665
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (250 microg) with clonidine (25 microg)
Study: 12651665
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (250 microg) with clonidine (75 microg)
Study: 12651665
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (250 microg)
Study: 10908006
Drug: Matrix treatment
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix treatment model for methamphetamine abuse
Study: 8516522
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral omeprazole
Study: 8516522
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of oral omeprazole
Study: 3552458
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg penbutolol with 6 mg piretanide
Study: 23318917
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using a pulsed 810-nm laser (average power 50 mW, peak power 80 W, 1,500 Hz, 120 s, 6 J, and 3.4 J/cm² per point) applied three times a week for 4 weeks
Study: 23318917
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (same application as LLLT but without energy output)
Study: 23591663
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral nutritional supplement drink containing 1.3 mg of vitamin B2, 1.4 mg of vitamin B6, 1.5 μg of B12, 200 μg of folic acid
Study: 2454376
Drug: Carvedilol (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25-50 mg)
Study: 29132880
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day)
Study: 27216406
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg betamethasone orally (n=50)
Study: 27216406
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg betamethasone parenterally (n=25)
Study: 27216406
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (oral, parenteral, control)
Study: 22572633
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg, p.o.) 24h before administration of radiocontrast agent and hydration (1mg/kg/hN/saline for 12h pre‐ and post‐contrast)
Study: 18405150
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral administration of Sibutramine)
Study: 16522834
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral azithromycin
Study: 8843511
Drug: Azelastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (2 mg; b.i.d.)
Study: 1398498
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 5 mg/kg body wt/day
Study: 1398498
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 10 mg/kg body wt/day
Study: 1398498
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 15 mg/kg body wt/day
Study: 1398498
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 20 mg/kg body wt/day
Study: 27091752
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (600,000 IU vitamin D3 as intramuscular injection)
Study: 25763201
Drug: CoQ10 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (200 mg/d)
Study: 22507468
Drug: 4% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% tetracaine gel (Ametop gel)
Study: 22507468
Drug: 4% liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% liposomal lidocaine gel (LMX4 gel)
Study: 22507468
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2.5% lidocaine and 2.5% prilocaine) applied for 30 min
Study: 22507468
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2.5% lidocaine and 2.5% prilocaine) applied for 60 min
Study: 20678674
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination treatment with OM 40 mg + AML 10 mg + HCTZ 25 mg
Study: 20678674
Drug: Dual combinations
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combinations (OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, AML 10 mg + HCTZ 25 mg)
Study: 20678674
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination treatment
Study: 15722295
Drug: Ketoprofen patch
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen patch (100 mg) applied once a day for 7 days
Study: 15722295
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied once a day for 7 days
Study: 10434823
Drug: Cuffed oropharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuffed oropharyngeal airway (COPA) as an adjunct to fibreoptic tracheal intubation
Study: 6260126
Drug: Tinidazole suppositories
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole suppositories
Study: 31156170
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with memantine
Study: 28742713
Drug: EN-EPA (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EN-EPA (2.2 g EPA/day)
Study: 12719078
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily in the evening
Study: 12719078
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% once daily in the evening
Study: 12719078
Drug: Travoprost 0.004%
Normalized name: TRAVOPROST 0.004% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004% once daily in the evening
Study: 10852765
Drug: Intravenous GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GSH 70 mg/kg/d
Study: 10852765
Drug: Intravenous GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GSH 70 mg/kg/d and intravenous NAC 75 mg/kg/d
Study: 10852765
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard septic shock therapy only)
Study: 8258959
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (ethyl esters, EPA+DHA = 7.7 g/day)
Study: 27509605
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at stellate ganglion combined with intravenous administration of alprostadil (10 µg) and sodium chloride solution (100 mL)
Study: 27509605
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of alprostadil (10 µg) and sodium chloride solution (100 mL)
Study: 25225285
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg bid for 24 weeks (Group A)
Study: 25225285
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg bid for 4 weeks, then 150 mg qd (Group B)
Study: 15014210
Drug: Atrial prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial prevention and termination therapies ON (n = 199)
Study: 15014210
Drug: Atrial prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial prevention and termination therapies OFF (n = 206)
Study: 15014210
Drug: Atrial prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial prevention and termination therapies ON (subgroup of 192 patients with a history of ATA's)
Study: 15014210
Drug: Atrial prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial prevention and termination therapies OFF (subgroup of 192 patients with a history of ATA's)
Study: 815188
Drug: Paracetamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol plus codeine (P + C) 350 + 20 mg
Study: 30862526
Drug: Daily undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily undulating periodization resistance training (DUP)
Study: 25415247
Drug: Combination 70%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination 70% mineralized: 30% demineralized FDBA
Study: 23489754
Drug: Minocycline pleurodesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline pleurodesis (300 mg)
Study: 21619621
Drug: Full-serve evidence
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-serve evidence service (database access, monthly e-mail alerts, and full-text article availability)
Study: 18028181
Drug: Antithrombotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic treatment initiation
Study: 18028181
Drug: Blockers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockers of the renin angiotensin system and statins
Study: 18028181
Drug: Atrial specific
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial specific antiarrhythmic drugs and direct thrombin inhibitors
Study: 12354317
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of long-term antipsychotic medication
Study: 9872197
Drug: Albuterol treatment
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol treatment (n=8)
Study: 9872197
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=7)
Study: 2750674
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin (12,500 U subcutaneously every 12 hours for 10 days)
Study: 2750674
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5,000 U subcutaneously every 12 hours for 10 days)
Study: 319692
Drug: Caffeine; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine; specific dosage and duration not mentioned
Study: 27995939
Drug: Telephone-based management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based management (weekly advice by telephone for 12 weeks)
Study: 25819700
Drug: Naltrexone (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (starting dose of 6.25mg, followed by long-acting injectable naltrexone)
Study: 22000810
Drug: Panitumumab 6
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg + FOLFIRI every 2 weeks
Study: 22000810
Drug: Panitumumab 9
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 9 mg/kg + irinotecan every 3 weeks
Study: 31099387
Drug: Losartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan + Amlodipine (L/A)
Study: 31099387
Drug: Losartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan + Hydrochlorothiazide (L/H)
Study: 27869476
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to maxillary incisors with a dose of 2 J/point, starting immediately after archwire insertion and repeated on specific days until the end of the leveling and alignment stage.
Study: 19135563
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg oral misoprostol
Study: 19135563
Drug: Both sublingual
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sublingual and oral misoprostol
Study: 15300958
Drug: clopidogrel/ASA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel/ASA combination
Study: 9737514
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (drug)
Study: 3361324
Drug: Heparin subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin subcutaneously three times daily (doses adjusted based on APTT)
Study: 3361324
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus 0.5 mg dihydroergotamine twice daily (fixed dose of 5,000 IU heparin)
Study: 25262178
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + DM60 (60 mg/day)
Study: 25262178
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + DM30 (30 mg/day)
Study: 16473748
Drug: Topical wheatgrass
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical wheatgrass cream applied twice daily for 6 weeks
Study: 16473748
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 6 weeks
Study: 12395691
Drug: Antidepressants (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (specific types not mentioned)
Study: 2270546
Drug: Indomethacin (3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (3% age oily solution)
Study: 2270546
Drug: Chlorphenol‐camphor‐menthol‐solution (ChKM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorphenol‐camphor‐menthol‐solution (ChKM) with procain on gauze strip
Study: 366141
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment of levamisole (150 mg per day)
Study: 366141
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment of levamisole (3 days per week, 150 mg)
Study: 366141
Drug: Weekly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly treatment of levamisole (150 mg one day per week)
Study: 366141
Drug: Proposed treatment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed treatment scheme of one single weekly dose of 150 mg
Study: 30784667
Drug: Long-term dual
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term dual antiplatelet therapy (DAPT) in non-high bleeding risk (HBR) patients
Study: 25052361
Drug: Medication optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication optimization at discharge (ACEI or ARB, β-blocker, MRA, diuretics)
Study: 25052361
Drug: Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatment procedures beyond pharmacotherapy
Study: 25052361
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence after 1 year
Study: 22399699
Drug: Twice-a-week supervised
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-week supervised aerobic and resistance training plus exercise counseling
Study: 19631844
Drug: Various restorative
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various restorative treatments
Study: 17049818
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable risperidone (50 mg/14 days)
Study: 16409880
Drug: Normal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hospital diet plus oral nutritional supplements (360 ml of 1.5 kcal/ml, 20 g of protein per day) until hospital discharge
Study: 10826395
Drug: Ca‐antagonist (manidipine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca‐antagonist (manidipine)
Study: 1813613
Drug: Amantadine (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (dopamine agonist)
Study: 15515153
Drug: Individual treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatments compared to control
Study: 12963896
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with a topical retinoid (e.g., adapalene) and an antibiotic
Study: 12963896
Drug: Topical retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoids alone
Study: 12963896
Drug: Topical or
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical or oral antibiotics
Study: 10235199
Drug: Domperidone 2
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 2 x 10‐mg tablets 4 times daily
Study: 10235199
Drug: Metoclopramide 1
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 1 x 10‐mg tablet + 1 placebo tablet 4 times daily
Study: 9094866
Drug: Non-antibiotics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotics
Study: 1811441
Drug: Improved ORS
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved ORS formulation (maltodextrin 20 g, glycine 4 g, glycyl-glycine 4 g)
Study: 1811441
Drug: Improved ORS
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved ORS formulation
Study: 31505228
Drug: Remestemcel-L
Normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remestemcel-L
Study: 30820060
Drug: Sulfamethoxazole-trimethoprim (SMX/TMP)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole-trimethoprim (SMX/TMP) 200/40 mg
Study: 30820060
Drug: Sulfamethoxazole-trimethoprim (SMX/TMP)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole-trimethoprim (SMX/TMP) 400/80 mg
Study: 21471414
Drug: Volar locking
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volar locking plate fixation with injection of calcium phosphate bone cement (Group 2)
Study: 19123930
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (aerobic and strength exercises) twice a week under supervision of a physiotherapist
Study: 11599648
Drug: Once-weekly fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly fluoxetine (90 mg/week)
Study: 11599648
Drug: Once-daily fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fluoxetine (20 mg/day)
Study: 9040303
Drug: Famciclovir 125
Normalized name: famciclovir 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 125 mg twice daily
Study: 8187255
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil 30 micrograms (0.6 ml) in 4.4 ml lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine
Study: 8187255
Drug: Lidocaine carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine (Control Group)
Study: 31530227
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) therapy (10 Hz, 600 pulses, 70% resting motor threshold amplitude)
Study: 31530227
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) therapy
Study: 31411696
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery
Study: 31411696
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF)
Study: 27649982
Drug: ONO-9054 (0.003%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-9054 (0.003%, 30 μg/mL) once daily for 28 days
Study: 27649982
Drug: Xalatan (0.005%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalatan (0.005%, 50 μg/mL) once daily for 28 days
Study: 24075603
Drug: Asenapine (ASE:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (ASE: 5-10mg twice-daily)
Study: 24075603
Drug: Olanzapine (OLA:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (OLA: 5-20mg once-daily)
Study: 19208649
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of unselected mononuclear cells (UNSEL)
Study: 19208649
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of selected CD34(+)CXCR4(+) cells (SEL)
Study: 19208649
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CTRL) without BM cell treatment
Study: 10853626
Drug: Aspirin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (low dosages < or = 100 mg/day)
Study: 10853626
Drug: Aspirin (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (higher dosages)